Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions.
Michelle T LeeJerin GeorgeHunaina ShahabMelody HermelJamal S RanaSalim S ViraniPublished in: Current atherosclerosis reports (2022)
Assessed studies examine a remotely delivered hypertension and lipid program in 10,000 patients across a diverse healthcare network; a cluster-randomized trial of a village doctor-led intervention for hypertension control; empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); efficacy and safety of empagliflozin in hospitalized heart failure patients (EMPULSE); icosapent ethyl versus placebo in outpatients with coronavirus disease 2019 (PREPARE-IT 2); clinical safety, pharmacokinetics, and low-density lipoprotein cholesterol-lowering efficacy of MK-0161, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; and effects of aspirin on dementia and cognitive impairment in the ASCEND trial. Research presented at the 2021 AHA Scientific Sessions emphasized the importance of interventions for cardiovascular disease prevention.
Keyphrases
- cardiovascular disease
- cognitive impairment
- ejection fraction
- coronavirus disease
- healthcare
- blood pressure
- end stage renal disease
- randomized controlled trial
- newly diagnosed
- low dose
- cardiovascular events
- type diabetes
- heart failure
- phase iii
- chronic kidney disease
- peritoneal dialysis
- mild cognitive impairment
- case control
- physical activity
- cardiovascular risk factors
- atrial fibrillation
- metabolic syndrome
- low density lipoprotein
- phase ii
- percutaneous coronary intervention
- health insurance